GenMark Diagnostics, Inc
GNMK
GNMK was delisted on the 21st of April, 2021.
96 hedge funds and large institutions have $571M invested in GenMark Diagnostics, Inc in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 45 increasing their positions, 18 reducing their positions, and 16 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 99 → 96 (-3)
13% less capital invested
Capital invested by funds: $657M → $571M (-$85.9M)
19% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$17M |
| 2 |
CC
Casdin Capital
New York
|
+$8.47M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$6.27M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$3.63M |
| 5 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
+$3.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$8.82M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.64M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$2.65M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.38M |
| 5 |
CRC
Curi RMB Capital
Chicago,
Illinois
|
-$2.26M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Invesco
Atlanta,
Georgia
| – | -$721K | -60,919 | Closed |
|
102
Ameriprise
Minneapolis,
Minnesota
| – | -$510K | -43,141 | Closed |
|
|
CM
103
Crestline Management
Fort Worth,
Texas
| – | -$426K | -36,046 | Closed |
|
|
LP
104
LMR Partners
London,
United Kingdom
| – | -$410K | -34,655 | Closed |
|
|
BFM
105
Boothbay Fund Management
New York
| – | -$165K | -13,954 | Closed |
|
106
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$137K | -11,578 | Closed |
|
|
BCM
107
BlueCrest Capital Management
St Helier,
Jersey
| – | -$126K | -10,693 | Closed |
|
|
CSS
108
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$76K | -6,454 | Closed |
|
109
Simplex Trading
Chicago,
Illinois
| – | -$31K | -2,622 | Closed |
|
|
PHK
110
Point72 Hong Kong
Hong Kong
| – | -$9K | -730 | Closed |
|
|
VWA
111
V Wealth Advisors
Overland Park,
Kansas
| – | -$4K | -300 | Closed |
|
112
Creative Planning
Overland Park,
Kansas
| – | -$2K | -200 | Closed |
|
GNMK Hedge Fund Activity: Q3 2017 in Review
96 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q3 2017, worth a combined $571M — down 13% from $657M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of GNMK and 13 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 45 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $17M. The largest seller was Citadel Advisors, cutting an estimated $8.82M.
- 96 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q3 2017, down from 99 in Q2 2017.
- Funds reported $571M of GenMark Diagnostics, Inc stock for Q3 2017, down 13% quarter-over-quarter.
- 13 funds opened new GenMark Diagnostics, Inc positions in Q3 2017 and 16 closed out, a net change of -3 holders.
- The largest GenMark Diagnostics, Inc buyer in Q3 2017 was T. Rowe Price Associates, an estimated $17M added.
- The largest GenMark Diagnostics, Inc seller in Q3 2017 was Citadel Advisors, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2017.